PROGRAM
DECEMBER 15-16-17 2022
Florence, ITALY
8:30
Opening Ceremony
(Welcome Greetings from representatives of the University of Florence, AOU Careggi, ISPRO and PAMM)
9:00
PAMM Oral Communications – Session 1
New therapeutics in thoracic malignancies: from bench to bedside
inaugural lecture
9:00-9:30
Major Advances in Metastatic NSCLC: Inactive state KRAS (G12C) inhibitors
Rafael Rosell (Catalan Institute of Oncology, Barcelona, Spain)
9:30-9:45
Improving precision oncology effectiveness in advanced NSCLC by exploiting a co-clinical platform
Paolo Bironzo (Università di Torino, Turin, Italy)
09:45-10:10
Molecular drivers and therapeutic targets of Lineage Plasticity in Lung Cancer
Triparna Sen (Memorial Sloan Kettering, New-York, USA)
10:10-11:10
Free communications from abstracts by PAMM members/collaborators :
4 Selected Abstracts
| Chairmen: |
Godefridus J. Peters (Amsterdam UMC, VU University, Amsterdam, The Netherlands and Medical University of Gdansk, Poland), Carmelo Tibaldi (Ospedale S. Luca, Lucca, Italy) |
10:10-10:25
Open reference resource for genomic copy number aberrations in cancer implementing emerging global standards
Michael Baudis (University of Zurich, Switzerland)
10:25-10:40
Fatty acid synthase as a novel prognostic biomarker and a potential therapeutic target in diffuse malignant peritoneal mesothelioma
Valentina Doldi (Fondazione IRCCS, Istituto Nazinale dei Tumori di Milano, Italy)
10:40-10:55
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models
Silvia La Monica (University of Parma, Parma, Italy)
10:55-11:10
B-raf inhibitors and diclofenac target glycolytic metabolism of BRAF-mutated thyroid carcinomas and synergistically restrain cell viability
Simona Cataldi (Institute of Genetics and Biophysics, Naples, Italy)
10:10
Open reference resource for genomic copy number aberrations in cancer implementing emerging global standards
Michael Baudis (University of Zurich, Switzerland)
11:10
Coffee-Break
11:30
Clinical Symposium 1
– Lung cancer therapeutics
11:30-12:00
Optimizing efficacy of immunotherapy with combinations
Marcello Tiseo (Università di Parma, Parma, Italy)
12:00-12:30
Why and how target KRAS in daily practice today
Fabrice Barlesi (Institut Gustave Roussy, Paris, France)
keynote lecture
12:30-13:00
Use of liquid biopsies to tailor actionable mutations in NSCLC
Christian Rolfo (Tisch Cancer Institute at Mount Sinai, New York, USA)
| Chairmen: |
Francesco Annunziato (Università di Firenze – AOU Careggi, Florence Italy), Nadia Zaffaroni (Istituto Nazionale Tumori Milano, Milan, Italy) |
13:00
Lunch
14:00
CANCER PHARMACOLOGY KEYNOTE LECTURE
– Target Selectivity in Drugs and Chemical Probes and the Pharmacological Audit Trail
Paul Workman (The Institute of Cancer Research, London, United Kingdom)
14:30
Clinical Symposium 2
– Gastrointestinal cancer therapeutics
14:30-15:00
Evolutionary landscape of treatment for BRAF mutant colorectal cancer
Andrea Sartore Bianchi (Università di Milano Statale – Ospedale Niguarda, Milan, Italy)
15:00-15:30
Tumor Mutational Burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer
Chiara Cremolini (Università di Pisa – AOUP, Pisa, Italy)
15:30-16:00
Precision oncology in metastatic colorectal cancer
Federica Di Nicolantonio (Università di Torino – IRCCS Candiolo, Turin, Italy)
16:00-16:30
Oesophago-gastric neoplasms and immunotherapy: a new deal for our patients ?
Gérard Milano (Université Côte d’Azur, Nice, France), Enrico Mini (Università di Firenze – AOU Careggi, Florence, Italy)
| Chairmen: |
Gérard Milano (Université Côte d’Azur, Nice, France), Enrico Mini (Università di Firenze – AOU Careggi, Florence, Italy) |
16:30
Coffee-Break
17:00
PAMM Oral Communications – Session 2
New therapeutics in thoracic malignancies: from bench to bedside
17:00-17:30
Biological underpinnings of pancreatic cancer chemoresistance
Elisa Giovannetti (Amsterdam UMC – Vrije Universiteit Amsterdam,
The Netherlands)
17:30-18:00
Molecular biomarkers for precision medicine in early colorectal cancer
Enrico Mini (Università di Firenze – AOU Careggi, Florence, Italy
18:00-18:30
New players in PDAC-TME: bacteria as biomarkers and potential therapeutic targets
Cindy Neuzillet (Institut Curie, Paris, France)
18:30-19:00
Free communications from abstracts by PAMM members/collaborators :
2 Selected Abstracts
| Chairmen: |
Andrea Galli (Università di Firenze – AOU Careggi, Florence, Italy), Jose Padron (University of La Laguna, Tenerife, Spain) |
18:30-18:45
Insight on pancreatic cancer nerves: uncovering the cross-talking between TGFβ and NGF and their impact on clinical outcomes
Rita Balsano (Cancer Center Amsterdam, Vrije Universiteit, Amsterdam, The Netherlands)
18:45-19:00
Investigation into Antigrowth Effect of Palladium(II)-Barbiturate Complex on Different Genetic Subtypes of Colon Cancer
Engin Ulukaya (Istinye University, Istanbul, Turkey)
19:00
PAMM BOARD MEETING
19:30
EORTC-PAMM MEETING, WELCOME COCKTAIL
8:30
Basic and Translational Research
Symposium 1 (Pharmacodynamics)
8:30-9:00
Preclinical development of self-assembly anion receptors with metal-dependent kinase inhibition as a novel class of anti-cancer compounds
Roger M. Phillips (University of Huddersfield Queensgate, Huddersfield, UK)
9:00-9:30
Cellular senescence in NSCLC: clinical relevance and preclinical evaluation of senescence-targeting strategies
An Wouters (University of Antwerp, Antwerp, Belgium)
09:30-10:30
Free communications from abstracts by PAMM members/collaborators :
4 Selected Abstracts
| Chairmen: |
Annette Larsen (Saint-Antoine Research Center, Paris, France), Paola Perego (Istituto Tumori Milano, Milan, Italy) |
9h30-9h45
Early Pharmacological Profiling of Antiproliferative Compounds by Continuous Live-Cell Imaging
José M. Padrón (Instituto Universitario de Bio-Orgánica Antonio González (IUBO-AG) , La Laguna, Canary Islands)
9:45-10:00
A reverse molecular pharmacology approach to unveil new therapeutic options in high-risk neuroblastoma
Marion Le Grand (CRCM, Marseille, France)
10:00-10:15
Combining sunitinib and anti-PD1 nivolumab is a valid strategy to enhance anti-cancer immunity and therapeutic potential in CRC
Roberta Di Fonte (IRCCS Istituto Tumori G.Paolo II, Bari, Italy)
10:15-10:30
Gender-related metabolic differences in melanoma: correlation with an immunosuppressive environment
Elisa Giannoni (Università di Firenze, Florence, Italy)
10:30
Coffee-Break
11:00
Clinical Symposium 3
– Breast and gynecological cancers therapeutics
11:00-11:30
PARP inhibitors in BRCA1- or BRCA2-Mutated Breast Cancer
Valentina Guarneri (Università di Padova, Padua, Italy)
11:30-12:00
PARP inhibitors in gynaecological cancers and beyond
Judith R.Kroep (Leiden University Medical Center, The Netherlands)
12:00-12:30
Targeting the PI3K pathway in HR-positive breast cancer
Fabrice André (Institut Gustave Roussy, Villejuif and Paris Saclay University, Orsay, France)
| Chairmen: |
Gianni Amunni (Università di Firenze – ISPRO, Florence, Italy), Andrea Bonetti (Ospedale Mater Salutis, Legnago, Italy) |
12:30
Clinical Keynote Lecture
– Car-T CELL and innovative therapies in oncology-Hematology
12:30-13:00
Title TBA
Gabriel Brisou (Paoli Calmettes Institute, Marseille, France)
13:00-13:30
Title TBA
Speaker TBA
13:30
Lunch
14:30
(Bio)technology Techniques Key Lecture 2
NGS in Predictive Molecular Pathology: from tissue to liquid biopsy
Umberto Malapelle (University Federico II of Naples, Naples, Italy)
15:00
Clinical Symposium 4
– Melanoma therapeutics and agnostic therapies
15:00-15:30
Sequential BRAF-MEK inhibition in BRAF V600 Mutation-Positive Advanced Melanoma
Michele Del Vecchio (Istituto Nazionale Tumori, Milan, Italy)
15:30-16:00
New combinations with I-O drugs in melanoma
Michele Maio (Università di Siena, Siena, Italy)
16:00-16:30
Reverse Molecular Pharmacology: using existing drugs to reveal novel vulnerabilities in refractory cancers
Eddy Pasquier (Aix-Marseille University, INSERM, France)
| Chairmen: |
Gabriella Nesi (Università di Firenze – AOU Careggi, Florence, Italy), Eric Raymond (Paris Saint-Joseph Hospital Group, Paris, France) |
16:30
Coffee-Break
17:00
PAMM Oral Communications – Session 3
New therapeutics in thoracic malignancies: from bench to bedside
17:00-17:30
Background relevance and preclinical/clinical activity of PPT1 inhibitors in patients with advanced cancer
Eric Raymond (Paris Saint-Joseph Hospital Group, Paris, France)
17:30-18:00
Gender-related metabolic differences in melanoma: correlation with an immunosuppressive environment
Elisa Giannoni (Università di Firenze, Florence, Italy)
18:00-18:45
Free communications from abstracts by PAMM members/collaborators :
3 Selected Abstracts
| Chairmen: |
Giovanni Codacci-Pisanelli (Università di Roma La Sapienza, Rome, Italy), Nicola Pimpinelli (Università di Firenze, Florence, Italy) |
18:00-18:15
Standardized immunohistochemical and pharmacological studies to evaluate Human Equilibrative Nucleoside Transporter 1 (hENT1)
Jisce Puik (Vrije Universiteit Amsterdam, The Netherlands)
18:15-18:30
Cytotoxic activity of novel 1,2,4-oxadiazole-based derivatives in pancreatic ductal adenocarcinoma by modulation of CDK1 and GSK3β
Camilla Pecoraro (Università degli Studi di Palermo, Italy)
18:30-18:45
GLUT-1: a new target/prognostic factor in Hepatobiliary cancers ?
Annalisa Comandatore (University of Pisa, Italy)
18:45
PAMM Business Meeting / General Assembly
20:30
Social Dinner
8:30
Basic and Translational Research
Symposium 2 (Pharmacodynamics)
SECTION 1 : PHARMACOKINETICS OF MONOCLONAL ANTIBODIES
08:30-9:00
Model informed precision dosing of Mabs in oncology : Challenges and opportunities
Dirk Jan Moes (Leiden University Medical Center, Leiden, The Netherlands)
9:00-9:30
TDM of monoclonal antibodies in oncology: hype or hope?
Joseph Ciccolini (Aix-Marseille University, Marseille, France)
SECTION 2 : Pharmacokinetics of protein kinase inhibitors and other anticancer drugs
09:30-10:00
Pharmacokinetic Considerations for Anticancer Therapy in Children
Georg Hempel (University of Münster, Münster, Germany)
10:00-10:30
Pharmacokinetics of antimetabolites in the modern era
Antonello Di Paolo (Università di Pisa, Pisa, Italy)
10:30-11:15
Free communications from abstracts by PAMM members/collaborators :
3 Selected Abstracts
| Chairmen: |
Georg Hempel (University of Münster, Münster, Germany), Marina Ziche (Università di Siena, Siena, Italy) |
10:30-10:45
Adaptive-dosing strategies of high dose Busulfan in bone-marrow transplant conditioning
Laure Carriat (Clinical Pharmacokinetics lab, Marseille, France)
10:45-11:00
Evaluation of targeted nano-architectures in alternative in vivo models of Head and Neck Squamous Cell Carcinoma
Patrizia Sarogni (Istituto Italiano di Tecnologia, Pisa, Italy)
11:00-11:15
Novel approaches to hamper cancer associated fibroblasts tumour support
Belen Toledo (University of Jaén, Spain)
11:15
Coffee-Break
11:35
Closing lecture
11:35-12:05
Role of EORTC in translational research to support (independent/academic) clinical studies in Europe
Winette Van der Graaf (Netherlands Cancer Institute, Amsterdam)
| Chairmen: |
Lorenzo Antonuzzo (Università di Firenze AOU Careggi, Florence, Italy) |
12:05
PAMM Oral Communications – Session 4
Basic and Translational Research: novel studies from early career investigators
12:05-13:20
Free communications from abstracts by PAMM members/collaborators :
4 Selected Abstracts
| Chairmen: |
Luigi Messori (Università di Firenze, Florence, Italy), Andrew D. Westwell (Cardiff University, Cardiff, UK) |
12:05-12:20
AXL emerges as a promising biomarker and target for pancreatic cancer
Benoit Immordino (Fondazione pisana per la Scienza, Pisa, Italy)
12:20-12:35
Enhanced cancer-selectivity and antitumour activity in carcinoma cell lines by transferrin receptor-targeted, apoferritin-encapsulated therapeutic agents
Tracey Bradshaw (University of Nottingham, UK)
12:35-12:50
New class of reversible benzylpiperidine-based monoacylglycerol lipase (MAGL) inhibitors displaying anti-proliferative activity in pancreatic ductal adenocarcinoma cells
Giulia Bononi (University of Pisa, Italy)
12:50-13:05
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer
Ingrid Garajova (University Hospital of Parma, Italy)
13:10
Best Oral Communication and Poster Prize and Closure
________________
Contact Industry & Logistics
Etienne JARRY
+33 (0)6 21 01 73 18
e.jarry@comnco.com
________________
Contact Registrations & Abstracts
Lucille Sarafian
l.sarafian@comnco.com
Zoé Vauthier
z.vauthier@comnco.com
Numéro d’agrément MedTech : EMT27399-PAMM EORTC 2022
